An Updated Systematic Review and Meta-analysis of Duloxetine for Knee Osteoarthritis Pain. Issue 11 (6th November 2021)

• Record Type: Journal Article
• Authors: Chen, Bo; Duan, Jingrui; Wen, Shengyue; Pang, Jian; Zhang, Min; Zhan, Hongsheng; Zheng, Yuxin
• Is Part Of: Clinical journal of pain. Volume 37:Issue 11(2021)
• Page Start: 852
• Page End: 862
• Publication Date: 2021-11-06
• Subjects: duloxetine -- knee osteoarthritis -- pain -- treatment; Pain -- Periodicals; Pain -- Treatment -- Periodicals; Analgesia -- Periodicals; 616.047205
• DOI: 10.1097/AJP.0000000000000975
• Languages: English
• ISSNs: 0749-8047

Abstract

Abstract : Objective: We conducted the updated systematic review and meta-analysis of the best available quantitative and qualitative evidence to evaluate the effects and safety of duloxetine for the treatment of knee osteoarthritis (OA) pain. Methods: A comprehensive literature search used 3 English and 4 Chinese biomedical databases from inception through July 10, 2020. We included randomized controlled trials of duloxetine with intervention duration of 2 weeks or longer for knee OA. The primary outcome was pain intensity measured by Brief Pain Inventory and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale. Secondary outcome measurements included 36-Item Short Form Health Survey, Patient's Global Impression of Improvement, Clinical Global Impressions of Severity, and adverse events (AEs). The quality of all included studies was evaluated using the Cochrane risk-of-bias criteria. The review was registered in the PROSPERO (CRD 42020194072). Results: Six studies totaling 2059 patients met the eligibility criteria. Duloxetine had significant reductions in Brief Pain Inventory 24 hours average pain (mean difference [MD]=−0.74; 95% confidence interval [CI], −0.92 to −0.57; P <0.00001; I 2 =13%; 5 trials; 1695 patients); patient general activity (MD=−0.76; 95% CI, −0.96 to −0.56; P <0.00001; I 2 =0%; 5 trials; 1694 patients) WOMAC physical function subscale (MD=−4.22; 95% CI, −5.14 to −3.30; P <0.00001; I 2 =26%; 5 trials; 1986 patients); Patient's Global Impression of Improvement (MD=−0.48; 95% CI, −0.58 to −0.37; P <0.00001; I 2 =29%; 5 trials; 1741 patients); and Clinical Global Impressions of Severity (MD=−0.34; 95% CI, −0.44 to −0.24; P <0.00001; I 2 =0%; 4 trials; 1178 patients) compared with placebo control. However, no difference on WOMAC pain subscale (standard mean difference=−1.68; 95% CI, −3.45 to 0.08; P =0.06; I 2 =100%; 3 trials; 1104 patients) and in serious AEs (risk ratio=0.92; 95% CI, 0.40-2.11; P =0.84; I 2 =0%; 5 trials; 1762 patients) between duloxetine and placebo. Furthermore, duloxetine failed to show superior effects for improving the life quality and demonstrated more treatment-emergent AEs. Conclusion: Duloxetine may be an effective treatment option for knee OA patients but further rigorously designed and well-controlled randomized trials are warranted.